Immunotherapy

SAN ANTONIO — The addition of atezolizumab to adjuvant chemotherapy “is very unlikely” to improve DFS for women with stage II or stage III triple-negative breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

Healio compiled the most-read news in allergy, asthma and immunology posted in November.

The first patient has been enrolled in a European phase 2b clinical trial for AD04, a novel immunotherapy for the treatment of mild Alzheimer’s disease, according to the manufacturer.

An international team of investigators has identified a drug candidate that nearly doubles survival rates for patients with diffuse midline glioma, an aggressive type of childhood brain tumor.

ANAHEIM, Calif. — Allergists can help adolescents and young adults with atopic conditions enlist in the military, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

The Society for Immunotherapy of Cancer has issued an update to its melanoma clinical practice guideline.

The number of cancer surgeries, chemotherapy treatments and radiation treatments declined dramatically during the first months of the COVID-19 pandemic, study findings published in JAMA Oncology showed.

In this episode, host Shikha Jain, MD, speaks with Kerry Reynolds, MD, about immunotherapy-related adverse events, creating educational resources on immunotherapy management and more.

Anti-PD-1 therapy reduces de novo production of spike-specific antibodies following vaccination from SARS-CoV-2, according to study findings presented at Society for Immunotherapy of Cancer Annual Meeting.